Recombinant novel coronavirus vaccine (CHO cells)

BIOLOGICAL5 trials

Sponsors

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Conditions

COVID-19Prevention of COVID-19

Phase 1

ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization

CompletedNCT05198102

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Prevention of COVID-19

Start: 2021-12-29End: 2022-07-19Updated: 2022-09-29

ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization

CompletedNCT05198063

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Prevention of COVID-19

Start: 2022-01-10End: 2022-12-06Updated: 2023-06-15

Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.COVID-19

Start: 2021-11-10End: 2022-07-31Target: 480Updated: 2022-01-24

Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac

CompletedNCT05205096

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.COVID-19

Start: 2021-11-10End: 2022-07-31Updated: 2023-09-18

Unknown Phase

To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2

CompletedNCT05895110

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.COVID-19

Start: 2022-04-29End: 2022-11-19Updated: 2023-06-08

Related Papers

Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.

2024-04-191 citations

Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older

Expert Review of Vaccines2023-10-25